Disitamab vedotin combined with apatinib in gastric cancer: A case report and review of literature

doi:10.5306/wjco.v15.i10.1351

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (181)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series.

Item

Count

PDF

HTML

149

Figures (1-3)

Sum=162

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=16

Oct 24, 2024 (publication date) through Sep 30, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Oncol. Oct 24, 2024; 15(10): 1351-1358
Published online Oct 24, 2024. doi: 10.5306/wjco.v15.i10.1351

Disitamab vedotin combined with apatinib in gastric cancer: A case report and review of literature

Xiao-Qian Li, Jing Yang, Bo Liu, Shu-Mei Han

Xiao-Qian Li, Jing Yang, Bo Liu, Shu-Mei Han, Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 510000, Shandong Province, China

Author contributions: Li XQ, Han SM written the draft of the manuscript; Liu B polished the manuscript and Yang J prepared figures; all authors commented on the previous versions of the manuscript; all authors read and approved the final manuscript.

Informed consent statement: The patient had sighed the Informed consent form.

Conflict-of-interest statement: No potential conflict of interest was reported by the author(s).

CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Shu-Mei Han, PhD, Associate Chief Physician, Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, No. 440 Jiyan Highway, Huaiyin District, Jinan 510000, Shandong Province, China. 15553115908@163.com

Received: April 15, 2024
Revised: August 18, 2024
Accepted: August 29, 2024
Published online: October 24, 2024
Processing time: 166 Days and 17.2 Hours

Core Tip

Core Tip: Apatinib exhibits synergistic effect with pan-HER inhibitor and reverses acquired resistance in human epidermal growth factor receptor 2 (HER2)-positive gastric cancer (GC) via stem cell factor/c-kit signaling and its downstream pathways. The patient treated with HER2-targeted therapy (disitamab vedotin, RC48) and small molecule antiangiogenesis targeted therapy with apatinib experiencing excellent survival, which provide related data for posterior line treatment of advanced GC.